Meeting News
-
Cell-free RNA Affords Another Tool in Lung Cancer Diagnosis and Treatment Monitoring
Although cell-free DNA (cfDNA) has emerged as the favored nucleic acid to analyze in liquid biopsy samples, there are situations when this marker fails to provided necessary information. In such cases, cell-free RNA (cfRNA) might help […]
-
Supporting the Detection of Early-Stage Disease with Use of Biomarkers
The NELSON trial and the US National Lung Cancer Screening Trial (NLST) marked major advances in lung cancer by establishing that low-dose computed tomography (LDCT) screening of high-risk individuals is effective at catching the disease in early […]
-
Leveraging ctDNA to Detect Minimal Residual Disease Following Surgery
Curative therapy remains elusive in early-stage NSCLC following surgical resection, sometimes even for patients with stage I disease. Adjuvant therapy can be of benefit, but only for a select few. As shown in the Lung Adjuvant […]
-
ctDNA Offers a Window Into Emerging Mechanisms of Resistance to Targeted Therapy
Targeted therapy has undoubtedly transformed the treatment landscape for metastatic NSCLC, with multiple agents now available to target seven different molecular drivers. In tandem with the growing treatment armamentarium, comprehensive molecular profiling has been critical in providing insight […]
-
Dr. Christian Rolfo Previews the New IASLC Consensus Statement on Liquid Biopsy
In his keynote address during the IASLC 2020 Hot Topic Meeting: Liquid Biopsy, co-chair Christian Rolfo, MD, PhD, MBA, provided an overview of the fastpaced evolution of liquid biopsy. In 2018, at the time of […]
-
FDA Perspectives on the Use of Liquid Biopsy in NSCLC
The US Food and Drug Administration (FDA) recognizes the value of liquid biopsy in managing patients with cancer, and the agency is actively working to bring these assays to the clinic. Harpreet Singh, MD, Director of […]
-
Biopsy Options Create New Decision-making Points for Clinicians
Understanding the differences in liquid biopsy approaches, as well as how they complement tissue, can be important to therapeutic selection and outcomes.
-
The RAMES Study: A New Strategy of Targeting Angiogenesis in Mesothelioma
At this year’s American Society of Clinical Oncology Virtual Meeting, the final results of the RAMES study were presented.1 RAMES was a prospective, placebo-controlled, phase II, randomized study in which […]
-
Elimination of Clinical Trial Disparities Requires a New Lens for Viewing Justice, New Approach to Patient’s Role
By Joy Curzio Although there has been tremendous progress in lung cancer over the past 10 years, with a number of new drug indications being approved in the United States […]
-
Immunotherapy, TKIs for Resectable/Resected NSCLC: Dr. Masahiro Tsuboi Provides a Comprehensive Overview of Promising Phase II Data, Phase III Status
By Jill Daigneault, PhD Surgical outcomes for early-stage NSCLC are still very poor due to the high rate of recurrence through distant metastases. It is likely that these distant metastases […]
View ILCN Archives
Provider Resources